Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Syntaxin: Secretion blockers

Mimicking nature is not a new drug discovery strategy, but understanding how botulinum neurotoxins work has provided Syntaxin Ltd. with a new molecular toolbox that last week attracted £16 million ($33.1 million) in a series B round.

Spun out of the U.K. Department of Health's Health Protection Agency (HPA) in November 2005, Syntaxin (Abingdon, U.K.) is leveraging knowledge of the structure and function of Clostridium neurotoxins, acquired over the past 15 years or so by its founder and CSO Keith Foster. The goal is

Read the full 831 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers